// App-Quantinova.ai

: Response to mepolizumab in patients with severe CRSwNP using EUFOREA 2021 criteria

Researchers

Presenter

  • Claire Hopkins

Principal Investigators

  • Joseph K Han

  • Valerie J Lund

  • Claus Bachert

  • Zuzana Diamant

  • Wystke Fokkens

  • Ana R Sousa

  • Steven G Smith

  • Shibing Yang

  • Bhabita Mayer

  • Steve W Yancey

  • Robert Chan

  • Stella E Lee

Medical Centers

  • Upper Airways Research Laboratory, Faculty of Medicine, Ghent University, Ghent, Belgium

  • Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America

  • Department of ENT, Guy’s Hospital and St Thomas’ Hospital, King’s College, London, United Kingdom

  • Royal National Throat Nose and Ear Hospital, London, United Kingdom

  • Department of Otolaryngology, Eastern Virginia Medical School, Norfolk, VA, United States of America

  • NCRI, London, United Kingdom

  • Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, United States.

  • Department of Intensive Care, Amsterdam University Medical Centers - location AMC, Amsterdam, Netherlands

  • Department of Microbiology Immunology & Transplantation, KU Leuven, Catholic University of Leuven, Leuven, Belgium

  • GSK R&D, Collegeville, United States of America

Locations

  • United States

  • United Kingdom

  • Netherlands

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Mepolizumab

  • Immunol

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved